Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2Active not recruiting 2Terminated 1Suspended 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 501Carcinoma, Renal Cell 165Urinary Bladder Neoplasms 135Carcinoma, Transitional Cell 71Carcinoma, Non-Small-Cell Lung 57Kidney Neoplasms 56Melanoma 53Breast Neoplasms 51Ovarian Neoplasms 43Neoplasms 41Neoplasm Metastasis 40Colorectal Neoplasms 38Lung Neoplasms 27Squamous Cell Carcinoma of Head and Neck 26Non-Muscle Invasive Bladder Neoplasms 26Uterine Cervical Neoplasms 25Stomach Neoplasms 25Sarcoma 24Endometrial Neoplasms 24Triple Negative Breast Neoplasms 21Pancreatic Neoplasms 19Esophageal Neoplasms 18Carcinoma, Hepatocellular 17Wilms Tumor 16Head and Neck Neoplasms 16Small Cell Lung Carcinoma 15Urologic Neoplasms 14Colonic Neoplasms 14Urethral Neoplasms 13Ureteral Neoplasms 13

Interventions

olaparib 1Pluvicto 1Lutetium-177 1Lutetium 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Metastatic Castration Resistant Prostate Cancer (mCRPC) × Genitourinary × Clear all
NCT06894511 2026-05-01

PSMAndARPI

Novartis

Phase 2 Active not recruiting
7 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT03874884 2025-05-14

LuPARP

Peter MacCallum Cancer Centre, Australia

Phase 1 Active not recruiting
70 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer (mCRPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡